Načítá se...
EZH1/2 Inhibitors Favor ILC3 Development from Human HSPC-CD34(+) Cells
SIMPLE SUMMARY: It has been well-demonstrated that EZH1/2 enzymes are involved not only in tumor development and progression, but also in the regulation of normal hematopoiesis from CD34(+)-HSPC. Given the crucial role of NK cells in tumor immune surveillance, in this study, we investigated whether...
Uloženo v:
| Vydáno v: | Cancers (Basel) |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
MDPI
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7830003/ https://ncbi.nlm.nih.gov/pubmed/33467134 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13020319 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|